Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients.

Skoglund, Karin ; Richter, Johan LU ; Olsson-Strömberg, Ulla ; Bergquist, Jonas ; Aluthgedara, Warunika ; Ubhayasekera, S J Kumari A ; Vikingsson, Svante ; Svedberg, Anna ; Söderlund, Stina and Sandstedt, Anna , et al. (2016) In Therapeutic Drug Monitoring 38(2). p.230-238
Abstract
CYP3A metabolic activity varies between individuals and is therefore a possible candidate of influence on the therapeutic outcome of the tyrosine kinase inhibitor imatinib in chronic myeloid leukemia (CML) patients. The aim of this study was to investigate the influence of CYP3A metabolic activity on the plasma concentration and outcome of imatinib in CML patients.
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Therapeutic Drug Monitoring
volume
38
issue
2
pages
230 - 238
publisher
Lippincott Williams & Wilkins
external identifiers
  • pmid:26693810
  • scopus:84951310669
  • pmid:26693810
ISSN
0163-4356
DOI
10.1097/FTD.0000000000000268
language
English
LU publication?
yes
id
65e40989-194a-4c96-9569-905b0ef3a4bc (old id 8503946)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26693810?dopt=Abstract
date added to LUP
2016-04-04 09:27:26
date last changed
2022-02-21 00:53:23
@article{65e40989-194a-4c96-9569-905b0ef3a4bc,
  abstract     = {{CYP3A metabolic activity varies between individuals and is therefore a possible candidate of influence on the therapeutic outcome of the tyrosine kinase inhibitor imatinib in chronic myeloid leukemia (CML) patients. The aim of this study was to investigate the influence of CYP3A metabolic activity on the plasma concentration and outcome of imatinib in CML patients.}},
  author       = {{Skoglund, Karin and Richter, Johan and Olsson-Strömberg, Ulla and Bergquist, Jonas and Aluthgedara, Warunika and Ubhayasekera, S J Kumari A and Vikingsson, Svante and Svedberg, Anna and Söderlund, Stina and Sandstedt, Anna and Johnsson, Anders and Aagesen, Jesper and Alsenhed, Jonas and Hägg, Staffan and Peterson, Curt and Lotfi, Kourosh and Gréen, Henrik}},
  issn         = {{0163-4356}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{230--238}},
  publisher    = {{Lippincott Williams & Wilkins}},
  series       = {{Therapeutic Drug Monitoring}},
  title        = {{In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients.}},
  url          = {{http://dx.doi.org/10.1097/FTD.0000000000000268}},
  doi          = {{10.1097/FTD.0000000000000268}},
  volume       = {{38}},
  year         = {{2016}},
}